Back to Search
Start Over
Toxicity of immunotherapy combinations with chemotherapy across tumor indications: Current knowledge and practical recommendations.
- Source :
- Cancer Treatment Reviews; Jun2024, Vol. 127, pN.PAG-N.PAG, 1p
- Publication Year :
- 2024
-
Abstract
- • Chemotherapy combinations with ICIs are the standard of care in several tumor types. • Immune related adverse events can mimic cytotoxic agents' toxicity however the management is very different. • Overlapping adverse events can present a challenge to clinicians in daily practice. • Differential work up is essential to determine the culprit drug and thus propose an adequate management strategy adapted for each type of adverse event. Chemotherapy associated with Immune Checkpoint Inhibitors is currently the standard of care in several tumor indications. This combination approach improves progression free survival (PFS), overall survival (OS) and complete pathological response (pCR) in several cancer types both in the early and metastatic approaches. However, the distinct spectrum of toxicities between cytotoxic side effects and immune related adverse events (irAEs) with similar clinical presentations and different management strategies remains a challenge in daily practice for healthcare professionals. This review summarizes the most common toxicities reported in the randomized clinical trials that led to the subsequent FDA approval of these combinations, across tumor indications. We cite in particular: non-small cell lung cancer, small cell lung cancer, triple negative breast cancer, squamous cell carcinoma of the head and neck, gastric carcinoma, esophageal carcinoma, cervical carcinoma and biliary tract carcinoma. We found that the combination of chemotherapy and immunotherapy was associated with an increased incidence of all grade adverse events (RR 1.11 [1.09; 1.12]) without an excess in treatment related mortality when compared to chemotherapy alone. We report also an increase in the incidence of serious adverse events (grade ≥ 3) (RR 1.16 [1.10;1.24]); in particular: high grade diarrhea, dyspnea, fatigue, rash and elevated liver enzymes. Together with the collaboration of our institutional network of organ specialists with expertise in irAEs, we propose practical recommendations for physicians to enhance clinical care and management of patients undergoing treatment with combined ICI immunotherapy and chemotherapy. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 03057372
- Volume :
- 127
- Database :
- Supplemental Index
- Journal :
- Cancer Treatment Reviews
- Publication Type :
- Academic Journal
- Accession number :
- 177314609
- Full Text :
- https://doi.org/10.1016/j.ctrv.2024.102751